Vivanza Biosciences Limited (VIVANZA) Fair Value & Analysis
Healthcare · IN · Market cap ₹76.0M
Fair value as of: Jul 6, 2026
From 15 valuation models · updated today
Share price +5.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1.70 – ₹2.61 · fair‑value band ₹1.26 – ₹2.10 · the ₹1.90 price screens above the ₹1.68 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vivanza Biosciences Limited (VIVANZA) currently trades at ₹1.90, while our model-based Fair Value estimate is ₹1.68 — implying the stock looks roughly 11.6% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Vivanza Biosciences Limited generated revenue of ₹1.2B at a net margin of 0.3%. It earns a return on equity of 9.5%. Net debt stands at ₹101M. The stock trades on a trailing P/E of 19.0. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹1.26 (bear case) to ₹2.10 (bull case); at ₹1.90, the current price sits within that range. The share trades about 30% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -12%, VIVANZA screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Vivanza Biosciences Limited engages in the research and development, manufacturing, and the distribution of pharmaceutical products in India. It offers latex surgical and examination, and latex free gloves, as well as other surgical products. The company was incorporated in 1982 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vivanza Biosciences Limited reported revenue of ₹1.2B in FY2025 versus ₹104M in FY2021, a compound +82.7%/yr. Reported net income was ₹3.9M in FY2025, compounding +4.3%/yr from FY2021.
Is VIVANZA fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vivanza Biosciences Limited (VIVANZA) undervalued?
What is the fair value of VIVANZA?
What is the quality score of VIVANZA?
What is the revenue of Vivanza Biosciences Limited (VIVANZA)?
What is the net profit margin of VIVANZA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.